Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EBSNASDAQ:GERNNASDAQ:LGNDNASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEBSEmergent Biosolutions$7.08+7.3%$6.11$4.02▼$15.10$384.30M2.091.75 million shs1.52 million shsGERNGeron$1.40+1.4%$1.44$1.17▼$5.06$891.69M0.6511.25 million shs10.31 million shsLGNDLigand Pharmaceuticals$113.66+1.0%$108.01$81.74▼$129.90$2.19B0.84117,947 shs106,499 shsMNKDMannKind$3.62+1.1%$4.29$3.53▼$7.63$1.10B0.972.43 million shs3.25 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEBSEmergent Biosolutions+3.29%-2.46%+3.86%+27.22%-6.66%GERNGeron-2.13%-10.97%-10.68%-13.21%-68.20%LGNDLigand Pharmaceuticals-0.99%-4.79%+9.10%+3.52%+32.66%MNKDMannKind-4.28%-10.28%-13.94%-28.69%-29.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEBSEmergent Biosolutions4.2013 of 5 stars3.51.00.04.61.42.51.3GERNGeron3.2788 of 5 stars3.41.00.01.32.41.70.6LGNDLigand Pharmaceuticals4.764 of 5 stars3.53.00.04.42.13.31.9MNKDMannKind2.8502 of 5 stars3.61.00.00.01.91.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEBSEmergent Biosolutions 3.00Buy$14.33102.45% UpsideGERNGeron 2.78Moderate Buy$5.06261.61% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.1428.58% UpsideMNKDMannKind 3.29Buy$10.33185.45% UpsideCurrent Analyst Ratings BreakdownLatest EBS, LGND, GERN, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/8/2025GERNGeronScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.504/10/2025LGNDLigand PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$143.004/10/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.004/9/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEBSEmergent Biosolutions$1.04B0.37$2.13 per share3.32$8.91 per share0.79GERNGeron$76.99M11.58N/AN/A$0.46 per share3.04LGNDLigand Pharmaceuticals$167.13M13.12$1.61 per share70.75$43.95 per share2.59MNKDMannKind$285.50M3.85$0.13 per share26.95($0.29) per share-12.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEBSEmergent Biosolutions-$190.60M-$2.71N/A3.42N/A-13.63%-0.52%-0.17%8/5/2025 (Estimated)GERNGeron-$174.57M-$0.21N/AN/AN/A-119.54%-47.86%-26.78%8/6/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$7.12N/A30.64N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)MNKDMannKind$27.59M$0.1036.2015.74N/A10.12%-32.41%10.85%8/6/2025 (Estimated)Latest EBS, LGND, GERN, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/7/2025Q1 2025EBSEmergent Biosolutions$0.49$0.71+$0.22$1.19$218.50 million$222.20 million5/7/2025Q1 2025GERNGeron-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEBSEmergent BiosolutionsN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEBSEmergent Biosolutions1.206.323.51GERNGeron0.447.876.97LGNDLigand PharmaceuticalsN/A5.275.02MNKDMannKindN/A2.362.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEBSEmergent Biosolutions78.40%GERNGeron73.71%LGNDLigand Pharmaceuticals91.28%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipEBSEmergent Biosolutions3.20%GERNGeron7.42%LGNDLigand Pharmaceuticals7.00%MNKDMannKind3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEBSEmergent Biosolutions2,42054.28 million52.54 millionOptionableGERNGeron70636.92 million589.66 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionableMNKDMannKind400303.93 million294.82 millionOptionableEBS, LGND, GERN, and MNKD HeadlinesRecent News About These CompaniesMannKind (NASDAQ:MNKD) Hits New 1-Year Low - What's Next?July 1 at 5:29 PM | marketbeat.comMannKind (NASDAQ:MNKD) Rating Lowered to Hold at Wall Street ZenJune 28, 2025 | americanbankingnews.comMannKind (NASDAQ:MNKD) Rating Lowered to "Hold" at Wall Street ZenJune 27, 2025 | marketbeat.comHealth Rounds: Inhaled insulin as good as injection for children at mealtimeJune 25, 2025 | reuters.comMannKind (NASDAQ:MNKD) Stock Price Down 5.6% - What's Next?June 25, 2025 | marketbeat.comLeerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy RatingJune 24, 2025 | insidermonkey.comMannKind Corporation (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from BrokeragesJune 24, 2025 | americanbankingnews.comMannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Buy" by BrokeragesJune 24, 2025 | marketbeat.comMannKind FY2026 EPS Forecast Decreased by Leerink PartnrsJune 19, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Reaches New 1-Year Low - Should You Sell?June 17, 2025 | marketbeat.comMannKind’s Afrezza: A Significantly Undervalued Investment Opportunity with Promising Clinical DataJune 16, 2025 | tipranks.comMannKind (NASDAQ:MNKD) Upgraded by Wall Street Zen to "Buy" RatingJune 14, 2025 | marketbeat.comInsider Selling: MannKind Co. (NASDAQ:MNKD) Director Sells 64,085 Shares of StockJune 11, 2025 | insidertrades.comInsider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD)June 10, 2025 | gurufocus.comMannKind Co. (NASDAQ:MNKD) Director Sells 64,085 SharesJune 10, 2025 | marketbeat.comMannKind’s Strategic Growth Potential and Market Positioning: A Buy RecommendationJune 10, 2025 | tipranks.comMannKind (NASDAQ:MNKD) Sets New 1-Year Low - Time to Sell?June 10, 2025 | marketbeat.comCantor Fitzgerald Estimates MannKind FY2026 EarningsJune 10, 2025 | marketbeat.comMannKind Corp (MNKD) to Showcase Inhaled Insulin at ADA's 85th Scientific Sessions | MNKD stock newsJune 9, 2025 | gurufocus.comMannKind Corporation to Showcase Inhaled Insulin Innovations at ADA's 85th Scientific SessionsJune 9, 2025 | quiverquant.comQMannKind to present inhaled insulin study at ADA eventJune 9, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEBS, LGND, GERN, and MNKD Company DescriptionsEmergent Biosolutions NYSE:EBS$7.08 +0.48 (+7.27%) Closing price 03:59 PM EasternExtended Trading$7.14 +0.06 (+0.92%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Geron NASDAQ:GERN$1.40 +0.02 (+1.45%) Closing price 04:00 PM EasternExtended Trading$1.42 +0.02 (+1.43%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Ligand Pharmaceuticals NASDAQ:LGND$113.66 +1.10 (+0.98%) Closing price 04:00 PM EasternExtended Trading$113.42 -0.23 (-0.21%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.MannKind NASDAQ:MNKD$3.62 +0.04 (+1.12%) Closing price 04:00 PM EasternExtended Trading$3.60 -0.02 (-0.55%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
